Bispecific Antibody-Drug Conjugates: Clinical Development and Future Directions
In the last decade, ADCs have been an emerging class of medical modalities to treat cancer by combining potent anti-cancer medicines (i.e., payloads) with monoclonal antibodies that deliver cancer medicines to the target cells. According to the market reports, the global ADC request size was valued at around 11.84 billion USD in 2024 and is […]